跳转至内容
Merck

SML1175

Sigma-Aldrich

罗咪酯肽

≥98% (HPLC), powder, histone deacetylase inhibitor

别名:

FK228, FR901228, L-缬氨酸, N-((3S,4E)-3-羟基-7-巯基-1-氧代-4-庚基)-D-戊基-D-半胱氨酸-(2Z)-2-氨基-2-丁烯氧基-, (4-1)-内酯,环状(1-2)-二硫化物, 环[(2Z)-2-氨基-2-丁烯酰基-L-戊基-(3S,4E)-3-羟基-7-巯基-4-庚烯酰基-D-戊基-D-半胱氨酰]环状(35)-二硫化物, 缩酚酸肽

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H36N4O6S2
分子量:
540.70
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

product name

罗咪酯肽, ≥98% (HPLC)

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 25 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

O=C(N/C(C(N[C@@H](C(C)C)C(O[C@@]1([H])CC2=O)=O)=O)=C\C)[C@@H](CSSCC/C=C/1)NC([C@H](N2)C(C)C)=O

InChI

1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1

InChI 密鑰

OHRURASPPZQGQM-GCCNXGTGSA-N

生化/生理作用

罗米地辛可促进细胞凋亡,同时阻碍神经胶质瘤模型中肿瘤的生长。
罗米地辛是HDAC1和HDAC2的一种非常有效的天然前药抑制剂,可被谷胱甘肽转化为活性形式。罗米地辛对HDAC1和HDAC2的IC50 值分别为36 nM和47 nM。它可杀死过表达Bcl-2和Bcl-XL的淋巴瘤细胞系,并已被批准用于治疗皮肤T细胞淋巴瘤(CTCL)和外周T细胞淋巴瘤,以及多种其他癌症。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Qin Xu et al.
American journal of physiology. Heart and circulatory physiology, 311(5), H1139-H1149 (2016-11-03)
Histone deacetylase (HDAC) inhibitors are small molecule anticancer therapeutics that exhibit limiting cardiotoxicities including QT interval prolongation and life-threatening cardiac arrhythmias. Because the molecular mechanisms for HDAC inhibitor-induced cardiotoxicity are poorly understood, we performed whole cell patch voltage-clamp experiments to
Sina Jostes et al.
Journal of cellular and molecular medicine, 21(7), 1300-1314 (2016-12-28)
Type II testicular germ cell cancers (TGCT) are the most frequently diagnosed tumours in young men (20-40 years) and are classified as seminoma or non-seminoma. TGCTs are commonly treated by orchiectomy and chemo- or radiotherapy. However, a subset of metastatic
Florencia Cayrol et al.
Nature communications, 8, 14290-14290 (2017-01-31)
Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poor response to chemotherapy and dismal survival. Identification of effective strategies to target PTCL biology represents an urgent need. Here we report that PTCL are sensitive to transcription-targeting drugs, and, in particular
Sara Moron-Lopez et al.
AIDS (London, England), 33(3), 425-431 (2018-12-12)
Reversing HIV-1 latency has been suggested as a strategy to eradicate HIV-1. We investigated the effect of romidepsin on the HIV transcription profile in participants from the REDUC part B clinical trial. Seventeen participants on suppressive antiretroviral therapy were vaccinated
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Iwamoto F M, et al.
Neuro-Oncology, 13(5), 509-516 (2011)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门